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Background: Insulin resistance (IR) is a well known cause of Heart failure (HF), but lately, HF has been shown to cause IR. During the course of 
advanced HF, diabetes mellitus is often difficult to control. The aim of this study was to evaluate the effect of left ventricular assist device (LVAD) 
support on diabetes in diabetic patients with advanced heart failure.
Methods: We preformed a retrospective chart review of diabetic patients implanted with LVAD at large single medical center. Clinical and 
laboratory parameters were collected one month prior to LVAD implantation and 4 month after LVAD implantation.
Results: Between July 2008 and July 2009, 15 diabetic patients were implanted and had complete follow-up data. 13 patients were male; mean 
age was 63±11 years. Pre-LVAD LVEF was 16.5±5.7%, and LVEDD was 6.8±1.1 cm. Diabetes control pre-LVAD was poor despite high dose insulin 
therapy (Table). Four months after LVAD implantation, fasting glucose levels, Hgb A1C, and insulin requirements were reduced substantially (Table). 
During the same time period, body weight increased from 87.9±16.0 to 93.2±12.3 kg (p=0.056).
Conclusions: Restoring cardiac output and decreasing HF severity with LVAD was associated with marked improvement of diabetic control in 
patients with DM and advanced HF. Prospective study of the effect of LVAD support on diabetes control and its mechanistic underpinnings is needed.
Pre-LVAD Post-LVAD P Value
Fasting Glucose (mg/dL) 157.7±50.6 104.1±21.4 < 0.001
HgB A1C (%) 7.7±0.9 6.0±0.8 < 0.001
Average Insulin daily dose (U/day) 55.3±51.7 24.2±27.2 0.07
Weight (Kg) 87.9±16.0 93.2±12.3 0.056
